Literature DB >> 20979454

Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.

Glendie Marcelin1, Hilliary M Bland, Nicholas J Negovetich, Matthew R Sandbulte, Ali H Ellebedy, Ashley D Webb, Yolanda S Griffin, Jennifer L DeBeauchamp, Janet E McElhaney, Richard J Webby.   

Abstract

Levels of preexisting antibodies to the hemagglutinin of pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1) virus positively correlate with age. The impact of contemporary seasonal influenza vaccines on establishing immunity to other pandemic H1N1 proteins is unknown. We measured serum antibodies to the neuraminidase (NA) of pandemic H1N1 in adults prior to and after vaccination with seasonal trivalent inactivated influenza vaccines. Serum antibodies to pandemic H1N1 NA were observed in all age groups; however, vaccination elevated levels of pandemic H1N1 NA antibodies predominately in elderly individuals (age, ⩾60 years). Therefore, contemporary seasonal vaccines likely contribute to reduction of pandemic H1N1-associated disease in older individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979454      PMCID: PMC2974032          DOI: 10.1086/657084

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Lack of association between titers of HAI antibody and whole-virus ELISA values for patients with congenital rubella syndrome.

Authors:  E J Hancock; K Pot; M L Puterman; A J Tingle
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

2.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

3.  Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes.

Authors:  Kristien Van Reeth; Vicki Gregory; Alan Hay; Maurice Pensaert
Journal:  Vaccine       Date:  2003-03-28       Impact factor: 3.641

4.  Eight-plasmid system for rapid generation of influenza virus vaccines.

Authors:  Erich Hoffmann; Scott Krauss; Daniel Perez; Richard Webby; Robert G Webster
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

5.  Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.

Authors:  André van Maurik; Nicolas Sabarth; Helga Savidis Dacho; Peter Brühl; Michael Schwendinger; Brian A Crowe; P Noel Barrett; Otfried Kistner; M Keith Howard
Journal:  Vaccine       Date:  2009-12-16       Impact factor: 3.641

6.  Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Authors:  Kathy Hancock; Vic Veguilla; Xiuhua Lu; Weimin Zhong; Eboneé N Butler; Hong Sun; Feng Liu; Libo Dong; Joshua R DeVos; Paul M Gargiullo; T Lynnette Brammer; Nancy J Cox; Terrence M Tumpey; Jacqueline M Katz
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

7.  Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.

Authors:  Z Chen; S Kadowaki; Y Hagiwara; T Yoshikawa; K Matsuo; T Kurata; S Tamura
Journal:  Vaccine       Date:  2000-08-01       Impact factor: 3.641

8.  A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens.

Authors:  Matthew R Sandbulte; Jin Gao; Timothy M Straight; Maryna C Eichelberger
Journal:  Influenza Other Respir Viruses       Date:  2009-09       Impact factor: 4.380

9.  In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.

Authors:  Yasushi Itoh; Kyoko Shinya; Maki Kiso; Tokiko Watanabe; Yoshihiro Sakoda; Masato Hatta; Yukiko Muramoto; Daisuke Tamura; Yuko Sakai-Tagawa; Takeshi Noda; Saori Sakabe; Masaki Imai; Yasuko Hatta; Shinji Watanabe; Chengjun Li; Shinya Yamada; Ken Fujii; Shin Murakami; Hirotaka Imai; Satoshi Kakugawa; Mutsumi Ito; Ryo Takano; Kiyoko Iwatsuki-Horimoto; Masayuki Shimojima; Taisuke Horimoto; Hideo Goto; Kei Takahashi; Akiko Makino; Hirohito Ishigaki; Misako Nakayama; Masatoshi Okamatsu; Kazuo Takahashi; David Warshauer; Peter A Shult; Reiko Saito; Hiroshi Suzuki; Yousuke Furuta; Makoto Yamashita; Keiko Mitamura; Kunio Nakano; Morio Nakamura; Rebecca Brockman-Schneider; Hiroshi Mitamura; Masahiko Yamazaki; Norio Sugaya; M Suresh; Makoto Ozawa; Gabriele Neumann; James Gern; Hiroshi Kida; Kazumasa Ogasawara; Yoshihiro Kawaoka
Journal:  Nature       Date:  2009-08-20       Impact factor: 49.962

10.  Preexisting immunity to pandemic (H1N1) 2009.

Authors:  Zheng Xing; Carol J Cardona
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

View more
  29 in total

1.  Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Mitch Phillips; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Int Immunol       Date:  2012-01-25       Impact factor: 4.823

2.  Fatal outcome of pandemic H1N1 2009 influenza virus infection is associated with immunopathology and impaired lung repair, not enhanced viral burden, in pregnant mice.

Authors:  Glendie Marcelin; Jerry R Aldridge; Susu Duan; Hazem E Ghoneim; Jerold Rehg; Henju Marjuki; Adrianus C M Boon; Jonathan A McCullers; Richard J Webby
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

Review 3.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

Review 4.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

5.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Authors:  Brendan M Giles; Stephanie J Bissel; Jodi K Craigo; Dilhari R Dealmeida; Clayton A Wiley; Terrence M Tumpey; Ted M Ross
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

Review 7.  Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness.

Authors:  Maryna C Eichelberger; David M Morens; Jeffery K Taubenberger
Journal:  Curr Opin Immunol       Date:  2018-04-16       Impact factor: 7.486

Review 8.  Cutaneous immunization: an evolving paradigm in influenza vaccines.

Authors:  Harvinder S Gill; Sang-Moo Kang; Fu-Shi Quan; Richard W Compans
Journal:  Expert Opin Drug Deliv       Date:  2014-02-12       Impact factor: 6.648

Review 9.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines.

Authors:  Robert B Couch; Robert L Atmar; Wendy A Keitel; John M Quarles; Janet Wells; Nancy Arden; Diane Niño
Journal:  Vaccine       Date:  2012-10-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.